“Durability of Response in Patients With Psoriatic Arthritis Treated With Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study”. 2020. SKIN The Journal of Cutaneous Medicine 4 (1): S2. https://skin.dermsquared.com/skin/article/view/801.